• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session

    12/21/22 1:51:35 PM ET
    $ADPT
    $AKTX
    $ALT
    $ATNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADPT alert in real time by email

    Gainers

    • Sintx Technologies, Inc. (NASDAQ:SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.
    • Venus Concept Inc. (NASDAQ:VERO) gained 63.3% to $0.4122 after the company announced it received a 510(k) clearance from the FDAto market its AI.ME next generation robotic technology for fractional skin resurfacing.
    • Laser Photonics Corporation (NASDAQ:LASE) jumped 40% to $2.1499 after the company announced it received an order from the largest glass manufacturer in North America.
    • Cenntro Electric Group Limited (NASDAQ:CENN) rose 33.6% to $0.3561. Cenntro started shipments of LS260 and LS100 vans to European Markets.
    • F-star Therapeutics, Inc. (NASDAQ:FSTX) gained 29.9% to $5.59.
    • Rekor Systems, Inc. (NASDAQ:REKR) jumped 28% to $0.7622. Rekor announced financing to solidify cash position and accelerate business growth and technology development.
    • Mobile Global Esports Inc. (NASDAQ:MGAM) jumped 25% to $0.7885. Maxim Group initiated coverage on Mobile Global Esports with a Buy rating and announced a price target of $1.5.
    • Kineta, Inc. (NASDAQ:KA) surged 25% to $4.70.
    • Blue Star Foods Corp. (NASDAQ:BSFC) gained 23.7% to $0.5319.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) rose 22.6% to $1.68.
    • BeyondSpring Inc. (NASDAQ:BYSI) gained 22.5% to $2.07.
    • Erayak Power Solution Group Inc. (NASDAQ:RAYA) gained 22.1% to $3.2955 after jumping over 47% on Tuesday.
    • Ecoark Holdings, Inc. (NASDAQ:ZEST) rose 21.4% to $0.34.
    • Grove Collaborative Holdings, Inc. (NYSE:GROV) rose 21% to $0.2476. Grove announced receipt of continued listing standards notice from NYSE.
    • Akari Therapeutics, Plc (NASDAQ:AKTX) gained 20.6% to $0.5347.
    • CalAmp Corp. (NASDAQ:CAMP) gained 20.1% to $4.12 after the company reported better-than-expected Q3 sales results.
    • DatChat, Inc. (NASDAQ:DATS) surged 19.4% to $0.4211.
    • Zymeworks Inc. (NASDAQ:ZYME) rose 18.6% to $8.40. Jazz Pharmaceuticals and Zymeworks announced that Jazz has exercised option to continue exclusive development and commercialization rights to Zanidatamab.
    • Evelo Biosciences, Inc. (NASDAQ:EVLO) jumped 18.5% to $1.73.
    • Pagaya Technologies Ltd. (NASDAQ:PGY) gained 18.4% to $0.7862.
    • Altimmune, Inc. (NASDAQ:ALT) gained 18.2% to $14.07. Altimmune announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with Non-Alcoholic Fatty Liver Disease (NAFLD).
    • Forian Inc. (NASDAQ:FORA) climbed 18.1% to $2.5750. New York has selected Forian's Biotrack as the State's Cannabis Seed to sale track and trace system.
    • Adaptive Biotechnologies Corporation (NASDAQ:ADPT) gained 17.7% to $8.35 after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $7.5 to $14.
    • Mereo BioPharma Group plc (NASDAQ:MREO) surged 16.2% to $0.6160.
    • Avaya Holdings Corp. (NYSE:AVYA) gained 14.6% to $0.2386.
    • NIKE, Inc. (NYSE:NKE) rose 13.9% to $117.51 after the company reported better-than-expected results for its second quarter on Tuesday.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) rose 13.2% to $0.3751 after dropping 27% on Tuesday.
    • Nine Energy Service, Inc. (NYSE:NINE) gained 12.7% to $11.89.
    • Six Flags Entertainment Corporation (NYSE:SIX) surged 12.3% to $23.50 after Land & Buildings issued a presentation highlighting an opportunity to unlock substantial real estate value at Six Flags. Land & Buildings is approximately a 3% shareholder of Six Flags.
    • Butterfly Network, Inc. (NYSE:BFLY) shares gained 11.1% to $2.4550. Butterfly Network recently completed successful deployment of 500 Butterfly iQ+ devices and training of 500+ healthcare workers across 224 facilities in Kenya.
    • 374Water, Inc. (NASDAQ:SCWO) jumped 10.8% to $2.77.
    • Energy Focus, Inc. (NASDAQ:EFOI) rose 7.6% to $0.3434 after declining 11% on Tuesday. Energy Focus, last month, posted a Q3 loss of $0.29 per share.
    • FedEx Corporation (NYSE:FDX) rose 4% to $170.79. FedEx posted upbeat earnings for its second quarter, while sales missed expectations. The company also said it sees FY23 earnings of $13.00 to $14.00 per share, versus analysts’ estimates of $14.08 per share.

     


    Losers

    • Pingtan Marine Enterprise Ltd. (NASDAQ:PME) shares fell 100% to $0.0001.
    • Meiwu Technology Company Limited (NASDAQ:WNW) dropped 78% to $0.4099.
    • Core Scientific, Inc. (NASDAQ:CORZ) shares dipped 50.5% to $0.1026 after the company filed for Chapter 11 bankruptcy.
    • IceCure Medical Ltd (NASDAQ:ICCM) fell 39.8% to $1.5650. IceCure reported pricing of 8,787,880 share public offering at $1.65 per share.
    • Celyad Oncology SA (NASDAQ:CYAD) fell 37.4% to $0.6516 after the company reported it has decided to discontinue the development of its remaining clinical program CYAD-211.
    • WeTrade Group, Inc. (NASDAQ:WETG) declined 25.7% to $0.2860.
    • Singularity Future Technology Ltd. (NASDAQ:SGLY) dropped 23.6% to $0.5599.
    • Vivos Therapeutics, Inc. (NASDAQ:VVOS) fell 20.7% to $0.42 after posting a loss for the third quarter.
    • Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) fell 20.6% to $3.7399.
    • UTime Limited (NASDAQ:UTME) fell 20% to $0.9998.
    • Ostin Technology Group Co., Ltd. (NASDAQ:OST) dropped 18.9% to $0.7773.
    • Quotient Limited (NASDAQ:QTNT) fell 17.8% to $0.2334.
    • Athenex, Inc. (NASDAQ:ATNX) fell 17% to $0.1327. Athenex announced Quantum Leap Healthcare Collaborative reported a trial result of I-SPY2 trial for oral paclitaxel in combination with PD-1 and carboplatin in neoadjuvant breast cancer.
    • Magenta Therapeutics, Inc. (NASDAQ:MGTA) dipped 15.9% to $0.33. BTIG maintained Magenta Therapeutics with a Buy and lowered the price target from $6 to $3.
    • Caravelle International Group (NASDAQ:CACO) dropped 15.2% to $1.79 after dropping 57% on Tuesday.
    • Rite Aid Corporation (NYSE:RAD) shares fell 13.9% to $11.89 after the company reported results for its third quarter.
    • Lion Group Holding Ltd. (NASDAQ:LGHL) fell 13.5% to $1.2450.
    • Surrozen, Inc. (NASDAQ:SRZN) dropped 13.4% to $0.43.
    • GEE Group, Inc. (NYSE:JOB) fell 12.6% to $0.5661 after the company reported worse-than-expected Q4 sales results.
    • Calavo Growers, Inc. (NASDAQ:CVGW) dropped 11.6% to $29.92 after the company reported worse-than-expected Q4 EPS and sales results.
    • BlackBerry Limited (NYSE:BB) fell 7.8% to $3.82 after the company reported Q4 earnings results.
    • Lanvin Group Holdings Limited (NYSE:LANV) dropped 7.8% to $6.76.
    • Cosmos Health Inc. (NASDAQ:COSM) fell 7.1% to $8.14 after gaining 15% on Tuesday. Cosmos Health recently announced pricing of a $32.5 million registered direct offering and concurrent private placement priced at-the-market.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) fell 6.6% to $7.89 after the company reported pricing of $75 million public offering.
    • Pebblebrook Hotel Trust (NYSE:PEB) fell 5.2% to $13.66 after the company lowered its FY22 FFO per share guidance.

    Read This Next: Bitcoin Edges Higher But Remains Below This Key Level; Helium Emerges As Top Gainer

    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT
    $AKTX
    $ALT
    $ATNX

    CompanyDatePrice TargetRatingAnalyst
    Core Scientific Inc.
    $CORZ
    3/3/2026$23.00Hold → Buy
    Needham
    FedEx Corporation
    $FDX
    2/25/2026$335.00Hold → Reduce
    HSBC Securities
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    FedEx Corporation
    $FDX
    2/13/2026$313.00 → $383.00Buy
    TD Cowen
    Terns Pharmaceuticals Inc.
    $TERN
    2/9/2026$58.00Outperform
    Leerink Partners
    FedEx Corporation
    $FDX
    2/3/2026$380.00Equal Weight → Overweight
    Wells Fargo
    FedEx Corporation
    $FDX
    2/3/2026$427.00Mkt Perform → Outperform
    Bernstein
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    More analyst ratings

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Core Scientific upgraded by Needham with a new price target

    Needham upgraded Core Scientific from Hold to Buy and set a new price target of $23.00

    3/3/26 10:31:14 AM ET
    $CORZ
    Finance: Consumer Services
    Finance

    FedEx downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded FedEx from Hold to Reduce and set a new price target of $335.00

    2/25/26 11:18:50 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    Cantor Fitzgerald initiated coverage on Surrozen with a new price target

    Cantor Fitzgerald initiated coverage of Surrozen with a rating of Overweight and set a new price target of $40.00

    2/19/26 7:52:22 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Rubinstein Julie exercised 68,328 shares at a strike of $8.53 and sold $1,211,737 worth of shares (81,342 units at $14.90), decreasing direct ownership by 2% to 643,471 units (SEC Form 4)

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    3/10/26 8:04:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for KLISYRI

    Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

    12/20/20 4:30:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000

    CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent ("LOI"), through its wholly owned subsidiary CosmoFarm S.A. ("CosmoFarm"), with respect to the acquisition of an extensive pharmacy distribution network from an established pharmaceutical company serving the Greek market for almost 40 years. The term of the LOI is ninety (90) days from March 6, 2026. The network currently generates approximately €10 million (approximately $11.5 million based on the prevailing EUR/USD exchange rate) in annual gross reve

    3/10/26 9:00:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

    CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Tuesday, March 17, 2026, at 11:00 am EDTUS: 1-888-407-2553Is

    3/10/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    SEC Filings

    View All

    Pebblebrook Hotel Trust filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Pebblebrook Hotel Trust (0001474098) (Filer)

    3/10/26 4:19:08 PM ET
    $PEB
    Real Estate Investment Trusts
    Real Estate

    GEE Group Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GEE Group Inc. (0000040570) (Filer)

    3/10/26 4:05:31 PM ET
    $JOB
    Diversified Commercial Services
    Consumer Discretionary

    Nike Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - NIKE, Inc. (0000320187) (Filer)

    3/9/26 4:33:25 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

    TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t

    2/26/26 9:10:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board

    CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development. Dr. Iliopoulos is a world-renowned expert in artificial intelligence, drug discovery, and drug development. He currently serves as Co-Founder and CEO of Athos Therapeutics Inc., an AI software and clinical-stage biotechnology company focused on developing precision therapeutics for autoimmun

    2/24/26 12:30:00 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

    SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

    11/15/24 10:35:07 AM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADPT
    $AKTX
    $ALT
    $ATNX
    Financials

    Live finance-specific insights

    View All

    IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

    CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2025 before the Nasdaq Stock Market opens on Tuesday, March 17, 2026. The Company will also discuss such results and other corporate developments on a conference call at 11:00 a.m. EDT on the same day. Conference call & webcast info:Tuesday, March 17, 2026, at 11:00 am EDTUS: 1-888-407-2553Is

    3/10/26 8:30:00 AM ET
    $ICCM
    Medical/Dental Instruments
    Health Care

    Pebblebrook Hotel Trust Schedules First Quarter 2026 Earnings Release and Conference Call

    Pebblebrook Hotel Trust (NYSE:PEB) (the "Company") today announced that it will report its financial and operating results for the quarter ending March 31, 2026, on Tuesday, April 28, 2026, after the market closes. The Company will conduct its quarterly conference call on Wednesday, April 29, 2026, at 9:00 AM ET. To participate in the conference call, please follow the steps listed below: On Wednesday, April 29, 2026, dial +1 (877) 407-3982 approximately ten minutes before the call begins (8:50 AM ET); Tell the operator that you are calling for Pebblebrook Hotel Trust's First Quarter 2026 Earnings Conference Call; State your full name and company affiliation, and you will be connect

    3/10/26 7:00:00 AM ET
    $PEB
    Real Estate Investment Trusts
    Real Estate

    Grove Announces Fourth Quarter and Full Year 2025 Financial Results

    Grove Collaborative Holdings, Inc. (NYSE:GROV) ("Grove" or the "Company"), the world's first plastic neutral retailer and a leading sustainable consumer products company, certified B Corporation, and Public Benefit Corporation, today reported financial results for its fiscal fourth quarter and year ended December 31, 2025. Key Fourth Quarter 2025 Financial Highlights: Total Revenue was $42.4 million, down 14.3% year-over-year Adjusted EBITDA was $1.6 million, compared to a loss of $1.6 million in the prior-year period Net Loss was $1.6 million, compared to Net Loss of $12.6 million in the prior-year period Operating cash flow was breakeven, compared to $0.3 million in the prio

    3/5/26 4:10:00 PM ET
    $GROV
    Catalog/Specialty Distribution
    Consumer Discretionary